Prothena Co. plc (NASDAQ:PRTA – Get Rating) CEO Gene G. Kinney sold 21,506 shares of the stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $32.83, for a total transaction of $706,041.98. Following the completion of the sale, the chief executive officer now directly owns 12,793 shares in the company, valued at $419,994.19. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Prothena Stock Up 2.6 %
Shares of PRTA stock opened at $33.11 on Friday. The firm has a market cap of $1.55 billion, a price-to-earnings ratio of 27.14 and a beta of 1.31. The company’s 50 day moving average is $28.49 and its 200 day moving average is $31.58. Prothena Co. plc has a 52-week low of $21.06 and a 52-week high of $79.75.
Prothena (NASDAQ:PRTA – Get Rating) last issued its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.07. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.23 million. Prothena had a net margin of 33.45% and a return on equity of 16.02%. Analysts anticipate that Prothena Co. plc will post -2.53 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Hedge Funds Weigh In On Prothena
Several institutional investors have recently bought and sold shares of the business. State Street Corp increased its holdings in Prothena by 20.0% during the first quarter. State Street Corp now owns 2,367,583 shares of the biotechnology company’s stock valued at $86,583,000 after buying an additional 394,633 shares during the period. First Light Asset Management LLC increased its holdings in Prothena by 13.3% during the first quarter. First Light Asset Management LLC now owns 1,838,548 shares of the biotechnology company’s stock valued at $67,236,000 after buying an additional 215,607 shares during the period. Dimensional Fund Advisors LP increased its holdings in Prothena by 0.4% during the first quarter. Dimensional Fund Advisors LP now owns 1,505,156 shares of the biotechnology company’s stock valued at $55,044,000 after buying an additional 6,619 shares during the period. Rock Springs Capital Management LP boosted its stake in Prothena by 2.4% in the first quarter. Rock Springs Capital Management LP now owns 663,530 shares of the biotechnology company’s stock valued at $24,265,000 after acquiring an additional 15,800 shares in the last quarter. Finally, Prosight Management LP boosted its stake in Prothena by 14.9% in the first quarter. Prosight Management LP now owns 566,538 shares of the biotechnology company’s stock valued at $20,718,000 after acquiring an additional 73,438 shares in the last quarter. 92.64% of the stock is owned by hedge funds and other institutional investors.
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
- Get a free copy of the StockNews.com research report on Prothena (PRTA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.